SAN DIEGO--(BUSINESS WIRE)--SynteractHCR, a leading full-service global contract research organization (CRO), congratulates Dr. Martine Dehlinger-Kremer, vice president of global medical and regulatory affairs, for being named one of the 2015 PharmaVOICE 100. PharmaVOICE magazine releases the list of the 100 most inspiring people in the life sciences industry annually, identifying industry thought leaders and innovators that have the biggest impact on the field. This year marks the fifth year that SynteractHCR executives have made the list.
With 28 years of experience in the clinical research industry, Dr. Dehlinger-Kremer has seen the evolution in complexity of trials and the impact of global trials on innovation. She has served as Chair of the Paediatric Working Group of EUCROF (the European CRO Federation) since 2008 and has influenced the standards, protocols and number of trials conducted for drugs being administered to children. Martine is also an advocate for alignment among various regulatory bodies in different countries to improve safety, increase efficiencies, reduce costs, and aid the international release of important drugs to patients who need them. She recently hosted a webinar on “The New EU Clinical Trials Regulation” and is frequently invited to speak on the topic at industry conferences.
The PharmaVOICE 100 has become a hallmark for the life sciences industry. Every year, thousands of nominations are submitted to PharmaVOICE by colleagues who believe their nominee fits the required criteria of providing inspiration to peers, coworkers and companies through their innovative approaches to addressing the industry’s myriad challenges. According to the magazine, “The PharmaVOICE 100 develop breakthrough strategies, products and services. They are known for pioneering new paths and lifting their companies to new heights. They also take the time to mentor the next generation of industry leaders.” The full list of honorees is showcased in the July/August 2015 issue of the magazine.
“Martine epitomizes the spirit of a PharmaVOICE 100 honoree,” said SynteractHCR CEO Wendel Barr. “She is a crusader for educating the industry on the complex, global regulatory landscape and on the nuances of conducting ethical, considerate clinical trials in one of the most vulnerable patient populations – children. As she dedicates herself wholeheartedly to bringing tomorrow’s treatments and a better future to patients, she reflects SynteractHCR’s philosophy of collaboration, flexibility and common purpose with our clients.’”
SynteractHCR is a full-service contract research organization with a successful two-decade plus track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.